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What’s known on the subject? and What does the study add?
• Radical nephroureterectomy (RNU), the standard of care treatment for high-risk urothelial carcinoma of the upper tract
(UTUC), results in loss of a renal unit. Loss of renal function decreases eligibility for systemic chemotherapies and
results in decreased overall survival in various malignancies.
• The study shows that only a small proportion of patients had a preoperative renal function that would allow
cisplatin-based chemotherapy. Moreover, eGFR signiﬁcantly decreased after RNU, thereby lowering the rate of cisplatin
eligibility to only 16 and 52% of patients based on the thresholds of 60 and 45 mL/min/1.73 m2, respectively. Taken
together with the rest of the literature, the ﬁndings of the study support the use of cisplatin-based chemotherapy, when
indicated, in the neoadjuvant rather than adjuvant setting.
Objective
• To report (i) the estimated glomerular ﬁltration rate
(eGFR) changes in patients undergoing radical
nephro-ureterectomy (RNU) for upper tract urothelial
carcinoma (UTUC); (ii) the rate of change in eGFR in
patients eligible for cisplatin-based chemotherapy; and (iii)
the association of preoperative, postoperative and rate of
change of renal function variables with survival outcomes.
Patient and Methods
• We performed a retrospective analysis of 666 patients
treated with RNU for UTUC at seven international
institutions from 1994 to 2007.
• The eGFR was calculated at baseline and at 3–6 months
(Modiﬁcation of Diet in Renal Disease formula (MDRD)
and Chronic Kidney Disease Epidemiology Collaboration
formula (CKD-EP) equations).
Results
• The median (interquartile range) eGFR decreased by
18.2 (8–12)% after RNU. A total of 37% of patients had
a preoperative eGFR  60 mL/min/1.73 m2, which
decreased to 16% after RNU (P < 0.001); 72% of
patients had a preoperative eGFR  45 mL/min/
1.73 m2, which decreased to 52% after RNU
(P < 0.001). The distributions were similar when
analyses were restricted to patients with locally
advanced disease (pT3–pT4) and/or lymph node
metastasis. Patients older than the median age of 70
years were more likely to have a decrease in eGFR after
RNU (P < 0.001).
• None of the renal function variables was associated
with clinical outcomes such as disease recurrence,
cancer-speciﬁc and overall mortality; however, when
analyses were restricted to patients who had no adjuvant
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chemotherapy and did not experience disease recurrence
(n = 431), a preoperative eGFR  60 mL/min/1.73 m2
(P = 0.03) and a postoperative eGFR  45 mL/min/
1.73 m2 (P = 0.04) were associated with better overall
survival in univariable analyses.
Conclusions
• In patients who had UTUC, eGFR was low and
furthermore, it signiﬁcantly decreased after RNU.
• Renal function did not aﬀect cancer-speciﬁc outcomes
after RNU.
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Introduction
Upper tract urothelial carcinoma (UTUC) is a relatively rare
neoplasm accounting for 5–6% of all urothelial tumours.
Radical nephro-ureterectomy (RNU) with excision of the
bladder cuﬀ is the standard of care treatment for high-risk
UTUC [1]. Despite its durable long-term disease control in
patients with early stage disease, the 5-year overall survival of
patients with non-organ-conﬁned UTUC is <50%, and for
those with nodal metastasis, it is only ~35% [2–4]. In patients
whose disease is detected at a point where surgical cure is
possible but risk of disease recurrence remains high (pT3
and/or lymph node metastasis), chemotherapy has been
considered as an option for adjuvant therapy [5–7]; however,
the timing of chemotherapy in UTUC is in debate as surgical
management of the disease, i.e. RNU, aﬀects a patient’s renal
function and thereby eligibility for adjuvant chemotherapy.
This strengthens the debate about neoadjuvant regimens
[8,9]. Moreover, in other malignancies, such as RCC, the
decrease in estimated GFR (eGFR) has been shown to
negatively aﬀect overall survival [10].
The aim of the present study was to report baseline eGFR
and changes in patients undergoing RNU for UTUC. In
addition, we wanted to report the eﬀect of RNU on
eligibility for cisplatin-based chemotherapy based on the
change in eGFR. Finally, we evaluated the association of
preoperative and postoperative renal function variables, as
well as their rate of change, with oncological outcomes and
overall survival.
Patients and Methods
Patients
In this institutional-review-board-approved study, all
participating sites provided the necessary institutional
data-sharing agreements before the initiation of the study.
A total of seven centres worldwide provided data. A
computerized databank was generated for data transfer.
After combining the datasets, reports were generated for
each variable to identify data inconsistencies and other data
integrity problems. Through regular communication with
all sites, resolution of all identiﬁed anomalies was achieved
before analysis. Before the ﬁnal analysis, the database was
frozen and the ﬁnal dataset was produced for the present
analysis. From 1994 to 2007, 781 patients underwent RNU
with bladder cuﬀ excision for UTUC. None of patients
received preoperative chemotherapy or radiotherapy.
Adjuvant chemotherapy was administered at the clinicians’
discretion based on tumour stage and overall health
status as well as patient preference (n = 62). Patients in
whom pre- and postoperative serum creatinine (Scr)
concentration data were not available were excluded from
the analyses (n = 115, 17.3%). These patients did not diﬀer
from the population of the study in terms of preoperative
characteristics.
Pathological Evaluation
All surgical specimens were processed according to
standard pathological procedures at each institution.
Tumours were staged according to the 2002 American Joint
Committee on Cancer/Union Internationale Contre le
Cancer TNM classiﬁcation [11]. Tumour grade was
assessed according to the 1998 WHO/International Society
of Urologic Pathology consensus classiﬁcation [12].
Histopathological assessment included concomitant
carcinoma in situ, tumour architecture (papillary or sessile
based on the predominant feature of the index lesion [13]),
lymphovascular invasion (deﬁned as the presence of
tumour cells within an endothelium-lined space without
underlying muscular walls [14]), and tumour necrosis
(deﬁned as the presence of microscopic coagulative
necrosis in >10% of the tumour [15]). Tumour location was
deﬁned as either renal pelvicalyceal or ureteric based on the
index cancer [16]. Tumour multifocality was deﬁned as the
synchronous presence of two or more pathologically
conﬁrmed tumours in any location (renal pelvis or ureter)
[17,18].
Follow-up
Patients were generally followed every 3–4 months for the
ﬁrst year after RNU, every 6 months from the second to the
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ﬁfth year, and annually thereafter. Follow-up consisted of a
history, physical examination, routine blood work, urinary
cytology, chest radiography, cystoscopic evaluation of the
urinary bladder, and radiographic evaluation of the
contralateral upper urinary tract. Elective bone scans, chest
CT, or MRI were performed when clinically indicated.
Disease recurrence was deﬁned as tumour relapse in the
operative ﬁeld, regional lymph nodes, and/or distant
metastasis. Cause of death was determined by treating
physicians, by chart review corroborated by death
certiﬁcates, or by death certiﬁcates alone. To reduce bias in
attribution of cause of death, only patients who had UTUC
listed in the death certiﬁcate were considered to have died
from UTUC for the present study [19]. All patients who
were coded as dead from cancer had previous disease
recurrence. Patients who died in the perioperative period
(i.e. within 30 days of surgery) were censored at time of
death for UTUC-speciﬁc survival analyses.
Renal Function Variables
We calculated eGFR at baseline and 3–6 months after RNU,
using the MDRD (GFR [mL/min/1.73 m2] = 175 ¥
[Scr]-1.154 ¥ [Age]-0.203 ¥ [0.742 if female] ¥ [1.212 if
African]) [20] and chronic kidney disease (CKD)-EPI (GFR
= 141 Xmin[Scr/k,1]a Xmax[Scr/k,1]-1.209 X 0.993Age X
1.018 [if female] X 1.159 [if black]) [21] equations. The two
equations have been shown to have substantial agreement
for baseline and follow-up eGFR [22].We used the median
value between the two equations (inter-equation coeﬃcient
variability of 0.94 and 0.96 for baseline and postoperative
data, respectively). In addition, we calculated the absolute
(eGFRfollow-up – eGFRbaseline) and percent change in eGFR
between preoperative and postoperative ([eGFRfollow-up –
eGFRbaseline] * 100/ eGFRbaseline).We also reported the
preoperative and postoperative number of patients with an
eGFR  60 mL/min per 1.73 m2 and an eGFR 
45 mL/min per 1.73 m2, and also the changes in CKD stage.
We chose an eGFR threshold of 60 mL/min per 1.73 m2,
which has traditionally deﬁned eligibility for full-dose
cisplatin therapy and a threshold of 45 mL/min per 1.73 m2,
which has been previously cited as a more strict deﬁnition
of CKD and has been shown to be associated with a higher
risk of comorbidities related to CKD.We then assessed the
impact of age (using the median age of our population
as the threshold) on the rate of change in renal function
after RNU.
Statistical Analysis
The Mann–Whitney U-test was used to compare
non-parametric continuous variables and a chi-squared
and Fisher’s exact tests to compare nominal variables.
Recurrence-free and cancer-speciﬁc and overall survival
curves were generated using the Kaplan–Meier method
and compared using the log-rank test. Univariable and
multivariable Cox regression models addressed outcomes
after RNU. All reported P-values are two-sided, and a P
value of 0.05 was considered to indicate statistical
signiﬁcance. Statistical analyses were performed with SPSS
(v20.0, IBM Corp, NY, USA).
Results
Clinicopathological Characteristics and Baseline
Renal Function
Overall 666 patients were included in the study. The
median (interquartile range [IQR]) age at surgery was 70
(54–76) years. The clinical and pathological characteristics
of the study population are shown in Table 1. The
preoperative and postoperative renal function
characteristics of the 666 patients are shown in Table 2; 249
patients (37%) had a preoperative eGFR  60 mL/min per
1.73 m2 and 479 (72%) had an eGFR  45 mL/min per
1.73 m2. The preoperative CKD stage distribution was:
CKD I (n = 32, 5%), CKD II (n = 217, 32.5%), CKD III (n =
386, 58%), CKD IV (n = 28, 4%), and CKD V (n = 3, 0.4%).
Postoperative Renal Function and Rates
of Change
After RNU, 105 patients (16%) had a postoperative eGFR 
60 mL/min per 1.73 m2 and 345 (52%) had an eGFR 
45 mL/min per 1.73 m2 (Table 2). The postoperative CKD
stages distribution was: CKD I (n = 7, 1%), CKD II (n = 98,
15%), CKD III (n = 460, 69%), CKD IV (n = 91, 13.5%) and
CKD V (n = 10, 1.5%). Comparison of preoperative and
postoperative Scr levels for each patient showed a mean
diﬀerence of 0.32 mg/dL (P < 0.001; Table 2), which
represents a median (IQR) increase of 24.8 (10–34)%. On
similar analysis performed for eGFR, we found a mean
diﬀerence between preoperative and postoperative eGFR of
10.2 mL/min per 1.73 m2 (P < 0.001), which represents a
median (IQR) decrease of 18.2 (8–12)%.
Preoperative, Postoperative and Rates of Change
of Renal Function Stratified by pT Stage and
Lymph Node Status
There was no diﬀerence either in terms of preoperative
eGFR between organ-conﬁned and non-organ-conﬁned
UTUC (57.3 vs 55.4, P = 0.73), nor in terms of
postoperative eGFR (46.3 vs 46.5, P = 0.19). The same
was true for lymph node status (P = 0.43 and P = 0.53,
respectively). 27.5% of patients with locally advanced
disease (pT3–pT4) and 32% of patients with pN+ stage
had a preoperative eGFR  60 mL/min per 1.73 m2, a
proportion that fell to 15 and 25%, respectively, after RNU.
Renal function changes after RNU
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Similarly, 69% patients with locally advanced disease
(pT3–pT4) and 66% of patients with pN+ stage disease had
a preoperative eGFR  45 mL/min per 1.73 m2, falling to
52 and 61%, respectively, after RNU. Finally, when
combining patients with pT3–pT4 and/or pN+ disease (n =
238), only 17.5% had a postoperative eGFR  60 and 54.5%
had a postoperative eGFR  45 mL/min per 1.73 m2.
Preoperative, postoperative and rates of change
of renal function stratified by patient's age
at surgery
The median age at surgery was 70 years and was chosen as
a threshold to stratify renal function (Table 2). Younger
patients (<70 years) were more likely to have a preoperative
eGFR  60 (44 vs 31%; P < 0.001) and 45 mL/min per
1.73 m2 (79 vs 66%; P < 0.001) compared with patients 
70 years. eGFR decreased signiﬁcantly after surgery in both
age groups; however, younger patients were also more
likely to maintain an eGFR  60 (21 vs 11%, P < 0.001)
and 45 mL/min per 1.73 m2 (61 vs 43%, P < 0.001).
Association of eGFR (Preoperative and
Postoperative) and Rates of Change with
Clinical Outcomes
At a median (IQR) follow-up of 45.5 (24–67) months, 212
patients (32%) experienced disease recurrence, 163
(24.5%) died from UTUC and 104 (15.5%) from other
causes. We addressed the association between renal
function variables (preoperative and postoperative eGFR
as a continuous variable or using thresholds of 60 and
45 mL/min per 1.73 m2, and the rates of change either
continuous or change in categorization) with disease
recurrence, cancer-speciﬁc and overall mortality. None
of these variables was associated with outcomes in
univariable analyses. Similarly, when restricting the
analyses to patients who did not experience disease
recurrence, none of the renal function variables was
associated with overall survival. The same was true when
patients were stratiﬁed by an age threshold of 70 years,
but when analyses were restricted to patients who had no
adjuvant chemotherapy and who did not experience
disease recurrence (n = 431), a preoperative eGFR 
60 mL/min per 1.73 m2 (P = 0.03, hazard ratio [HR]: 0.64,
CI: 0.42–0.97) and a postoperative eGFR  45 mL/min
per 1.73 m2 (P = 0.04, HR: 0.67, CI: 0.45–0.99) were
associated with better overall survival in univariable
analyses (Fig. 1A and B). These factors were not
independently associated with overall survival in
multivariable analyses which adjusted for standard
clinico-pathological features (P = 0.72, HR: 1.11, CI:
0.59–2.10 and P = 0.11, HR: 0.61, CI: 0.33–1.13).
Discussion
We conﬁrmed that eGFR decreases signiﬁcantly after
RNU [8,9]. We found an 18% decrease in eGFR after
RNU, which was similar to the rates reported in previous
studies (22–24%) [8,9]. This rate of decrease was
independent of the pathological features. Younger patients
(<70 years) were more likely to have a better preoperative
eGFR and to maintain it postoperatively than older
patients (70 years). This is in contrast to the ﬁndings of
Kaag et al. [9] who did not ﬁnd a statistically signiﬁcant
diﬀerence between age categories. The diﬀerences between
that and the present study are probably attributable to
diﬀerences in samples size and patient characteristics such
as age distribution.
Table 1 Clinicopathological characteristics of 666 patients treated
with RNU for UTUC.
Median, IQR age, years 69.6 (54–76)
Gender, n (%)
Male 441 (66)
Female 225 (34)
Body mass index, kg/m2
Mean (SD) 28.5 (5.5)
Median (IQR) 28.2 (24–32)
ECOG performance status, n (%)
0 445 (67)
1–3 221 (33)
Previous bladder cancer, n (%)
Yes 244 (37)
No 422 (63)
Primary tumour location, n (%)
Renal pelvis 420 (63)
Ureteral 246 (37)
Multifocality, n (%)
Yes 164 (25)
No 502 (75)
Surgical approach, n (%)
Open 519 (78)
Laparoscopic 147 (22)
pT stage, n (%)
pT0-pTa-pTis-pT1 326 (49)
pT2 118 (18)
pT3 182 (27)
pT4 40 (6)
Grade, n (%)
No Tumour 12 (2)
Low 121 (18)
High 533 (80)
Lymph node status, n (%)
pN0 291 (44)
pNx 291 (44)
pN+ 84 (12)
Concomitant carcinoma in situ, n (%)
Present 229 (34)
Absent 437 (66)
Lymphovascular invasion*, n (%)
Present 171 (31)
Absent 380 (69)
Adjuvant chemotherapy, n (%)
Yes 62 (9)
No 604 (91)
ECOG, European Cooperative Oncology Group. *Lymphovascular invasion
information was available only in 551 patients (83%).
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We found that only a small proportion of patients with
high-risk UTUC were eligible for adjuvant chemotherapy
based on eGFR. Moreover, the rate of eligibility decreased
dramatically after RNU. The role and beneﬁt of
adjuvant chemotherapy for locally advanced and/or
lymph-node-positive UTUC remains controversial [23].
Although a small single-centre retrospective series reported
a beneﬁt in overall survival in 32 patients [5], two
retrospective international studies could not conﬁrm these
results (n = 121 and n = 143) [6,7]. By contrast, two
retrospective studies using systemic chemotherapy in the
neoadjuvant setting (n = 107 and n = 82) found a 14–15%
complete remission (pT0) rate [24,25]. Extrapolating from
lower tract urothelial carcinoma, and based on cumulative
evidence, the neoadjuvant setting seems the most
eﬀective way of administrating systemic cisplatin-based
chemotherapy in UTUC [26,27]. This is even more
important in UTUC because eligibility for cisplatin-based
chemotherapy is heavily based on renal function, which
decreases after RNU [8,9].We chose an eGFR threshold of
60 mL/min per 1.73 m2, which has traditionally deﬁned
eligibility for full-dose cisplatin therapy and also represents
Table 2 Baseline and postoperative renal function of the 666 patients treated with RNU for UTUC.
Preoperative Postoperative P
SCr, mg/dL <0.001
Mean (SD) 1.29 (0.48) 1.61 (1.2)
Median (IQR) 1.20 (1–1.5) 1.3 (1–2)
eGFR mL/min per 1.73 m2
MDRD <0.001
Mean (SD) 56.1 (18.4) 45.9 (15.8)
Median (IQR) 54.8 (43–66) 45.5 (35–54)
CDK-EPI <0.001
Mean (SD) 57.2 (18.4) 46.8 (16.9)
Median (IQR) 55 (44–69) 46 (35–57)
eGFR(MDRD+CDK-EPI)/2 <0.001
Mean (SD) 56.6 (18) 46.3 (16.3)
Median (IQR) 56.1 (43–68) 45.9 (35–55)
eGFR  60 mL/min per 1.73 m2 pT stage, n (%) 249 (37) 105 (16) <0.001
pT stage, n (%) <0.001
pT0-pTis-pTa-pT1 138 (56) 60 (57)
pT2 40 (16) 12 (11)
pT3 53 (21) 25 (24)
pT4 18 (7) 8 (8)
Lymph node status, n (%) <0.001
pNx 119 (48) 45 (43)
pN0 103 (41) 39 (37)
pN+ 27 (11) 21 (20)
eGFR  45 mL/min per 1.73 m2, n (%) 479 (72) 345 (52) <0.001
pT stage, n (%) <0.001
pT0-pTis-pTa-pT1 240 (50) 172 (50)
pT2 87 (18) 57 (16)
pT3 124 (26) 92 (27)
pT4 28 (6) 24 (7)
Lymph node status <0.001
pNx 216 (45) 141 (41)
pN0 208 (43) 153 (44)
pN+ 55 (12) 51 (15)
70 years old
SCr, mg/dL <0.001
Mean (SD) 1.29 (0.42) 1.61 (1.15)
eGFR mL/min per 1.73 m2 <0.001
Mean (SD) 52.9 (16.9) 43.5 (15.2)
eGFR  60 mL/min per 1.73 m2, n (%) 107 (31) 36 (11) <0.001
eGFR  45 mL/min per 1.73 m2, n (%) 225 (66) 148 (43) <0.001
<70 years old
SCr, mg/dL <0.001
Mean (SD) 1.29 (0.55) 1.61 (1.26)
Median (IQR)
eGFR mL/min per 1.73 m2 <0.001
Mean (SD) 60.6 (19) 49.4 (16.8)
Median (IQR)
eGFR  60 mL/min per 1.73 m2, n (%) 142 (44) 69 (21) <0.001
eGFR  45 mL/min per 1.73 m2, n (%) 255 (79) 198 (61) <0.001
Renal function changes after RNU
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the transition into stage III CKD, and a threshold of
45 mL/min per 1.73 m2, which has been previously cited as
a more strict deﬁnition of CKD and has been shown to be
associated with a higher risk of comorbidities related to
CKD [28]. Based on the eGFR threshold of 60 mL/min per
1.73 m2, 37% of patients were eligible for neoadjuvant
cisplatin-based chemotherapy and only 16% were
candidates for adjuvant chemotherapy.With the threshold
Patient numbers at risk for overall survival 
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12 24 36 48 60 72 84 96 108 120 132 144 156
Preoperative eGFR
≥60 mL/min/1.73 m2
175 140 118 101 82 67 56 50 42 28 20 14 10 6
Preoperative eGFR
<60 mL/min/1.73 m2
256 218 180 143 122 100 74 56 44 31 23 13 4 3
Preoperative
eGFR 2-years ± SE 5-years ± SE 7-years ± SE 
≥60 88% ± 3% 77% ± 4% 72% ± 5%
<60 88% ± 2% 76% ± 4% 63% ± 5%
eGFR <60
mL/min/1.73 m2
eGFR >60 
mL/min/1.73 m2
P = 0.03
Patient numbers at risk for overall survival 
Months 0 12 24 36 48 60 72 84 96 108 120 132 144 156
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Postoperative eGFR
≥45 mL/min/1.73 m2 
217 175 142 117 93 77 64 56 49 36 25 16 10 7
Postoperative eGFR
<45 mL/min/1.73 m2
214 183 156 127 111 90 66 50 37 23 18 11 4 2
Postoperative
eGFR 2-years ± SE 5-years ± SE 7-years ± SE
≥45 88% ± 3% 80% ± 3% 75% ± 4%
<45 93% ± 2% 73% ± 4% 59% ± 5%
eGFR >45
mL/min/1.73 m2
eGFR <45
mL/min/1.73 m2
P = 0.04
Fig. 1 A, Overall survival in patients without
adjuvant chemotherapy and who did not
experience disease recurrence. B, Overall
survival in patients without adjuvant
chemotherapy and who did not experience
disease recurrence.
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of 45 mL/min per 1.73 m2, 72% of patients were eligible for
neoadjuvant cisplatin-based chemotherapy while only 52%
were candidates for adjuvant chemotherapy. Thus, in
addition to possible associated reasons, the decrease in
eGFR after RNU supports the use of cisplatin-based
chemotherapy for high-risk UTUC in a neoadjuvant rather
than adjuvant setting. The pertinent and remaining
question is the identiﬁcation of candidates for systemic
chemotherapy [2] but, even more so than in bladder
urothelial carcinoma, deﬁciencies in clinical staging make
the accurate identiﬁcation of patients who have advanced
disease and are therefore the best candidates for systemic
chemotherapy extremely diﬃcult.
We did not ﬁnd any association between eGFR,
irrespective of categorization of the data, with oncological
outcomes and overall survival. CKD has been associated
with a signiﬁcant increase in cardiovascular events and
death from any cause, independently of competing
comorbidities [28]. In RCC, a decrease in eGFR has been
associated with overall survival [10,29,30], but in the
present study, renal function features (preoperative,
postoperative and rate of change) were not associated
with recurrence-free and cancer-speciﬁc survival,
probably owing to the fact that cancer features had a
stronger eﬀect on outcomes. The lack of association with
overall survival could be attributable to the short
follow-up (45 months) of patients who did not succumb
to their UTUC; however, when excluding from the
analyses patients who experienced disease recurrence and
those who underwent adjuvant chemotherapy, a
preoperative eGFR  60 and a postoperative eGFR 
45 mL/min per 1.73 m2 were associated with overall
survival. Larger cohorts with longer follow-up in patients
who do not succumb to their disease are necessary to fully
assess the association of eGFR with overall survival in
patients who underwent RNU.
The present study has several limitations, including those
inherent to a retrospective multicentre study design.We
did not perform a centralized pathological review, which
could have led to misinterpretations of pathological
features. We used eGFR rather than creatinine clearance.
Although patients with CKD stage 5 were present in the
study, patients with comorbidities and/or CKD
preoperatively may have been preferentially selected for
conservative management. We acknowledge that medical
comorbidities (e.g. hypertension and diabetes mellitus)
could aﬀect the renal function of these patients.
Unfortunately, information on comorbidities was not
available in our database, so we were unable to include
this in the present analyses. In addition, the short
follow-up and low number of non-cancer-speciﬁc events
may have limited the statistical signiﬁcance of some
analyses.
In conclusion, only a small proportion of patients
had a preoperative renal function that would allow
cisplatin-based chemotherapy. Furthermore, eGFR
signiﬁcantly decreased after RNU, thereby lowering the rate
of cisplatin eligibility to only 16 and 52% of patients, based
on the thresholds of 60 and 45 mL/min per 1.73 m2,
respectively. Older patients (70 years) had a lower
baseline eGFR than younger patients and older patients
(70 years) had a proportionally higher rate of decrease in
eGFR after RNU. Neither preoperative nor postoperative
eGFR variables aﬀected cancer-speciﬁc and overall survival
outcomes after RNU. Taken together with the rest of the
literature, the present ﬁndings support the use of
cisplatin-based chemotherapy, when indicated, in the
neoadjuvant rather than adjuvant setting.
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